Page last updated: 2024-11-02

pioglitazone and Acute Liver Injury, Drug-Induced

pioglitazone has been researched along with Acute Liver Injury, Drug-Induced in 49 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Research Excerpts

ExcerptRelevanceReference
" Liver failure associated with rosiglitazone or pioglitazone was defined as liver injury accompanied by hepatic encephalopathy, liver transplantation, placement on a liver transplant list, or death in which all other likely etiologies were excluded."7.75Case series of liver failure associated with rosiglitazone and pioglitazone. ( Barbehenn, E; Floyd, JS; Lurie, P; Wolfe, SM, 2009)
"The aim of this study was to assess the incidence of liver failure in association with antidiabetic treatment using pioglitazone vs."7.73Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone. ( Iyer, S; Perez, A; Rajagopalan, R, 2005)
"Pioglitazone was effective in decreasing serum HCV RNA at day-14 (n = 10; difference of means = 205,618 IU/ml; 95% CI 26,600 to 384,600; P<0."6.77Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study. ( Buck, M; Chojkier, M; Donohue, M; Elkhayat, H; Sabry, D, 2012)
" Liver failure associated with rosiglitazone or pioglitazone was defined as liver injury accompanied by hepatic encephalopathy, liver transplantation, placement on a liver transplant list, or death in which all other likely etiologies were excluded."3.75Case series of liver failure associated with rosiglitazone and pioglitazone. ( Barbehenn, E; Floyd, JS; Lurie, P; Wolfe, SM, 2009)
"The aim of this study was to assess the incidence of liver failure in association with antidiabetic treatment using pioglitazone vs."3.73Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone. ( Iyer, S; Perez, A; Rajagopalan, R, 2005)
"Pioglitazone was effective in decreasing serum HCV RNA at day-14 (n = 10; difference of means = 205,618 IU/ml; 95% CI 26,600 to 384,600; P<0."2.77Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study. ( Buck, M; Chojkier, M; Donohue, M; Elkhayat, H; Sabry, D, 2012)
" This is further supported by experimental data that demonstrate that troglitazone, alone among the thiazolidinediones, is toxic in hepatocyte cell culture."2.42Hepatotoxicity of the thiazolidinediones. ( Chandramouli, J; Tolman, KG, 2003)
"The first thiazolidinedione derivative drug for diabetes, troglitazone, was found to cause fatal hepatotoxicity, although it was judged as safe during the clinical trial."2.41[Evaluation of thiazolidinedione derivative drugs for safety]. ( Iwata, M; Kobayashi, M, 2001)
"particularly type 2 diabetes mellitus, and is associated with a higher risk of atherosclerosis and cardiovascular complications."2.41Hepatotoxicity with thiazolidinediones: is it a class effect? ( Scheen, AJ, 2001)
"Tamoxifen (TAM) is a chemotherapeutic drug widely utilized to treat breast cancer."1.91Pioglitazone attenuates tamoxifen-induced liver damage in rats via modulating Keap1/Nrf2/HO-1 and SIRT1/Notch1 signaling pathways: In-vivo investigations, and molecular docking analysis. ( Elariny, HA; Kamel, GAM, 2023)
"Acetaminophen has a reasonable safety profile when consumed in therapeutic doses."1.40Protective effect of pioglitazone, a PPARγ agonist against acetaminophen-induced hepatotoxicity in rats. ( Candasamy, M; Chellappan, DK; Dua, K; Gubbiyappa, KS; Gupta, G; Krishna, G, 2014)
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."1.37FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011)
"The frequency of edema and cardiac failure was significantly higher with TZDs than in other patients (18% and 7."1.37Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database. ( Berthet, S; Lapeyre-Mestre, M; Montastruc, JL; Olivier, P, 2011)
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."1.36Developing structure-activity relationships for the prediction of hepatotoxicity. ( Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010)
"Troglitazone is a thiazolidinedione insulin sensitizer drug that is metabolized mainly to a sulfate conjugate (M-1) in humans."1.32Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. ( Goto, A; Nakajima, M; Nezu, J; Nozawa, T; Sugiura, S; Tamai, I; Tsuji, A; Yokoi, T, 2004)
"Pioglitazone was promptly discontinued because her symptoms were consistent with those of hepatic dysfunction and pioglitazone was identified as a potential cause."1.32Second-generation thiazolidinediones and hepatotoxicity. ( Blevins, SM; Britton, ML; Marcy, TR, 2004)
"Pioglitazone prevented increase in plasma aspartate transaminase, alanine aminotransferase, and TNF-alpha levels but had no effect on plasma and hepatic levels of lipid peroxide."1.32Pioglitazone prevents acute liver injury induced by ethanol and lipopolysaccharide through the suppression of tumor necrosis factor-alpha. ( Hashimoto, K; Hokkyo, K; Nakajima, H; Ohata, M; Sakamoto, K; Suzuki, H; Toda, G; Yamada, H; Yamauchi, M, 2004)
"Pioglitazone is an oral hypoglycemic agent in the thiazolidinedione class."1.31Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. ( Kram, MT; Lefkowitch, JH; May, LD; Rubin, DE, 2002)

Research

Studies (49)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's29 (59.18)29.6817
2010's18 (36.73)24.3611
2020's2 (4.08)2.80

Authors

AuthorsStudies
Nozawa, T1
Sugiura, S1
Nakajima, M1
Goto, A1
Yokoi, T1
Nezu, J1
Tsuji, A1
Tamai, I1
Yamamoto, K1
Itoh, T1
Abe, D1
Shimizu, M1
Kanda, T1
Koyama, T1
Nishikawa, M1
Tamai, T1
Ooizumi, H1
Yamada, S1
Greene, N1
Fisk, L1
Naven, RT1
Note, RR1
Patel, ML1
Pelletier, DJ1
Morgan, RE2
Trauner, M1
van Staden, CJ2
Lee, PH1
Ramachandran, B1
Eschenberg, M1
Afshari, CA2
Qualls, CW1
Lightfoot-Dunn, R1
Hamadeh, HK2
Ekins, S1
Williams, AJ1
Xu, JJ1
Chen, M2
Vijay, V1
Shi, Q2
Liu, Z2
Fang, H2
Tong, W3
Dawson, S1
Stahl, S2
Paul, N1
Barber, J1
Kenna, JG2
Ding, D1
Kelly, R1
Sakatis, MZ1
Reese, MJ1
Harrell, AW1
Taylor, MA1
Baines, IA1
Chen, L1
Bloomer, JC1
Yang, EY1
Ellens, HM1
Ambroso, JL1
Lovatt, CA1
Ayrton, AD1
Clarke, SE1
Warner, DJ1
Chen, H1
Cantin, LD1
Walker, CL1
Noeske, T1
Chen, Y1
Kalyanaraman, N1
Kalanzi, J1
Dunn, RT1
Aleo, MD1
Luo, Y1
Swiss, R1
Bonin, PD1
Potter, DM1
Will, Y1
Suzuki, A1
Thakkar, S1
Yu, K1
Hu, C1
Norman, BH1
Kamel, GAM1
Elariny, HA1
Chang, JH1
Sangaraju, D1
Liu, N1
Jaochico, A1
Plise, E1
Meng, YK1
Li, CY1
Li, RY1
He, LZ1
Cui, HR1
Yin, P1
Zhang, CE1
Li, PY1
Sang, XX1
Wang, Y1
Niu, M1
Zhang, YM1
Guo, YM1
Sun, R1
Wang, JB1
Bai, ZF1
Xiao, XH1
Mak, A1
Kato, R1
Weston, K1
Hayes, A1
Uetrecht, J1
Gupta, G1
Krishna, G1
Chellappan, DK1
Gubbiyappa, KS1
Candasamy, M1
Dua, K1
Floyd, JS1
Barbehenn, E1
Lurie, P1
Wolfe, SM1
Osei, SY1
Koro, CE1
Cobitz, AR1
Kolatkar, NS1
Stender, M1
Tolman, KG2
Freston, JW2
Kupfer, S1
Perez, A2
Beiderbeck, AB1
Sakaguchi, M1
Berthet, S1
Olivier, P1
Montastruc, JL1
Lapeyre-Mestre, M1
Chojkier, M1
Elkhayat, H1
Sabry, D1
Donohue, M1
Buck, M1
Kawamori, R2
Kobayashi, M3
Iwata, M3
Hiratani, K1
Kaplowitz, N1
Lewis, JH1
Watkins, PB1
Hisamochi, A1
Kumashiro, R1
Koga, Y1
Tanaka, E1
Ide, T1
Hino, T1
Murashima, S1
Ogata, K1
Kuwahara, R1
Koga, H1
Shishido, S1
Ueno, T1
Sata, M1
Eguchi, T1
Chandramouli, J1
Marcy, TR1
Britton, ML1
Blevins, SM1
Ohata, M1
Suzuki, H1
Sakamoto, K1
Hashimoto, K1
Nakajima, H1
Yamauchi, M1
Hokkyo, K1
Yamada, H1
Toda, G1
Amin, P1
Rajagopalan, R1
Iyer, S1
Slavin, DE1
Schlichting, CL1
Enomoto, N1
Takei, Y1
Yamashima, S1
Ikejima, K1
Kitamura, T1
Sato, N1
Da Silva Morais, A1
Abarca-Quinones, J1
Horsmans, Y1
Stärkel, P1
Leclercq, IA1
Martínez Odriozola, P1
Ibarmia Lahuerta, J1
Gutiérrez Macías, A1
de la Villa, FM1
Kanazawa, A1
Haruta, T1
Krentz, AJ1
Bailey, CJ1
Melander, A1
Gale, EA1
Maeda, K1
Scheen, AJ1
May, LD1
Lefkowitch, JH1
Kram, MT1
Rubin, DE1
Nierenberg, DW1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Comparator Controlled, Double-Blind Study of the Liver Safety of Pioglitazone HCl vs Glyburide With Metformin and Insulin as Part of Step Therapy in Subjects With Type 2 (Non-Insulin Dependent) Diabetes[NCT00494312]Phase 42,120 participants (Actual)Interventional2000-10-31Completed
A Randomized, Partially Blinded, Pilot Study of the Effects of Pioglitazone on HCV RNA in Overweight Subjects With Chronic HCV Genotypes 1 or 4 Infection.[NCT01157975]Phase 20 participants (Actual)Interventional2008-10-31Withdrawn (stopped due to Study was completed in another site)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

9 reviews available for pioglitazone and Acute Liver Injury, Drug-Induced

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Pr

2016
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.
    Journal of medicinal chemistry, 2020, 10-22, Volume: 63, Issue:20

    Topics: Animals; Cell Line; Cell Survival; Chemical and Drug Induced Liver Injury; Drug Discovery; Drug Eval

2020
[Pioglitazone].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 9

    Topics: Animals; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Edema; Humans; Hypoglyce

2002
Hepatotoxicity of the thiazolidinediones.
    Clinics in liver disease, 2003, Volume: 7, Issue:2

    Topics: Chemical and Drug Induced Liver Injury; Chromans; Humans; Hypoglycemic Agents; Liver Failure, Acute;

2003
[Adverse effects of insulin sensitisers and biguanides].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Oct-28, Volume: 65 Suppl 8

    Topics: Acidosis, Lactic; Animals; Biguanides; Capillary Permeability; Chemical and Drug Induced Liver Injur

2007
[Clinical evaluation of pioglitazone].
    Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58, Issue:2

    Topics: Animals; Blood Glucose; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Female; G

2000
Lessons from the glitazones: a story of drug development.
    Lancet (London, England), 2001, Jun-09, Volume: 357, Issue:9271

    Topics: Adverse Drug Reaction Reporting Systems; Chemical and Drug Induced Liver Injury; Chromans; Diabetes

2001
[Evaluation of thiazolidinedione derivative drugs for safety].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59, Issue:11

    Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Edema; Heart Fa

2001
Hepatotoxicity with thiazolidinediones: is it a class effect?
    Drug safety, 2001, Volume: 24, Issue:12

    Topics: Aged; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellitus,

2001

Trials

2 trials available for pioglitazone and Acute Liver Injury, Drug-Induced

ArticleYear
Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US.
    Drug safety, 2009, Volume: 32, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Chemical and Drug Induced Liver Injury; D

2009
Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study.
    PloS one, 2012, Volume: 7, Issue:3

    Topics: Adult; Antiviral Agents; Blood Glucose; Chemical and Drug Induced Liver Injury; Cytokines; Female; G

2012

Other Studies

38 other studies available for pioglitazone and Acute Liver Injury, Drug-Induced

ArticleYear
Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity.
    Drug metabolism and disposition: the biological fate of chemicals, 2004, Volume: 32, Issue:3

    Topics: Biological Transport, Active; Chemical and Drug Induced Liver Injury; Chromans; Cloning, Molecular;

2004
Identification of putative metabolites of docosahexaenoic acid as potent PPARgamma agonists and antidiabetic agents.
    Bioorganic & medicinal chemistry letters, 2005, Feb-01, Volume: 15, Issue:3

    Topics: Animals; Binding Sites; Chemical and Drug Induced Liver Injury; COS Cells; Diabetes Mellitus, Experi

2005
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship;

2010
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des

2011
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters

2012
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
    PLoS computational biology, 2011, Volume: 7, Issue:12

    Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da

2011
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme

2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters

2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily

2013
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
    Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:3

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters

2014
Pioglitazone attenuates tamoxifen-induced liver damage in rats via modulating Keap1/Nrf2/HO-1 and SIRT1/Notch1 signaling pathways: In-vivo investigations, and molecular docking analysis.
    Molecular biology reports, 2023, Volume: 50, Issue:12

    Topics: Animals; Antioxidants; Chemical and Drug Induced Liver Injury; Inflammation; Kelch-Like ECH-Associat

2023
Comprehensive Evaluation of Bile Acid Homeostasis in Human Hepatocyte Co-Culture in the Presence of Troglitazone, Pioglitazone, and Acetylsalicylic Acid.
    Molecular pharmaceutics, 2019, 10-07, Volume: 16, Issue:10

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bile Acids and Salts; Cells, Cultured; Chemical an

2019
Cis-stilbene glucoside in Polygonum multiflorum induces immunological idiosyncratic hepatotoxicity in LPS-treated rats by suppressing PPAR-γ.
    Acta pharmacologica Sinica, 2017, Volume: 38, Issue:10

    Topics: Animals; Chemical and Drug Induced Liver Injury; Emodin; Fallopia multiflora; Glucosides; Lipopolysa

2017
Editor's Highlight: An Impaired Immune Tolerance Animal Model Distinguishes the Potential of Troglitazone/Pioglitazone and Tolcapone/Entacapone to Cause IDILI.
    Toxicological sciences : an official journal of the Society of Toxicology, 2018, 02-01, Volume: 161, Issue:2

    Topics: Animals; Antibodies, Monoclonal; Catechols; Cell Line; Chemical and Drug Induced Liver Injury; CTLA-

2018
Protective effect of pioglitazone, a PPARγ agonist against acetaminophen-induced hepatotoxicity in rats.
    Molecular and cellular biochemistry, 2014, Volume: 393, Issue:1-2

    Topics: Acetaminophen; Animals; Chemical and Drug Induced Liver Injury; Lipid Peroxidation; Pioglitazone; PP

2014
Case series of liver failure associated with rosiglitazone and pioglitazone.
    Pharmacoepidemiology and drug safety, 2009, Volume: 18, Issue:12

    Topics: Adverse Drug Reaction Reporting Systems; Aged; Chemical and Drug Induced Liver Injury; Databases, Fa

2009
Commentary on 'Case series of liver failure associated with rosiglitazone and pioglitazone' by Floyd et al.
    Pharmacoepidemiology and drug safety, 2009, Volume: 18, Issue:12

    Topics: Adverse Drug Reaction Reporting Systems; Chemical and Drug Induced Liver Injury; Diabetes Mellitus,

2009
Commentary on 'Case series of liver failure associated with rosiglitazone and pioglitazone' by James Floyd et al.
    Pharmacoepidemiology and drug safety, 2009, Volume: 18, Issue:12

    Topics: Adverse Drug Reaction Reporting Systems; Chemical and Drug Induced Liver Injury; Diabetes Mellitus,

2009
Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database.
    BMC clinical pharmacology, 2011, May-24, Volume: 11

    Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Databases, Factual; Diabetes Mellitus, Type 2;

2011
[Biguanide, pioglitazone and alpha-glucosidase inhibitors].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 6

    Topics: Acidosis, Lactic; Biguanides; Body Weight; Chemical and Drug Induced Liver Injury; Digestive System;

2012
[Meta-analysis shows: insulin sensitizer is safe for the liver].
    MMW Fortschritte der Medizin, 2002, Oct-03, Volume: 144, Issue:40

    Topics: Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type

2002
Did this drug cause my patient's hepatitis?
    Annals of internal medicine, 2003, Jan-21, Volume: 138, Issue:2

    Topics: Chemical and Drug Induced Liver Injury; Chromans; Humans; Pioglitazone; Product Surveillance, Postma

2003
[A case of drug induced liver injury related pioglitazone].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2003, Volume: 100, Issue:3

    Topics: Aryl Hydrocarbon Hydroxylases; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP2C9; Diab

2003
Second-generation thiazolidinediones and hepatotoxicity.
    The Annals of pharmacotherapy, 2004, Volume: 38, Issue:9

    Topics: Adult; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycem

2004
Pioglitazone prevents acute liver injury induced by ethanol and lipopolysaccharide through the suppression of tumor necrosis factor-alpha.
    Alcoholism, clinical and experimental research, 2004, Volume: 28, Issue:8 Suppl Pr

    Topics: Animals; Chemical and Drug Induced Liver Injury; Ethanol; Female; Lipopolysaccharides; Liver Disease

2004
Liver toxicity and pioglitazone: data are missing.
    BMJ (Clinical research ed.), 2004, Oct-16, Volume: 329, Issue:7471

    Topics: Chemical and Drug Induced Liver Injury; Humans; Hypoglycemic Agents; Pioglitazone; Thiazolidinedione

2004
Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone.
    Diabetes, obesity & metabolism, 2005, Volume: 7, Issue:2

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Chemical and Drug Induced Liver In

2005
Rating the severity of the medical consequences of drug-induced liver injury.
    Regulatory toxicology and pharmacology : RTP, 2005, Volume: 43, Issue:2

    Topics: Chemical and Drug Induced Liver Injury; Chromans; Data Collection; Humans; Hypoglycemic Agents; Live

2005
Protective effect of pioglitazone against endotoxin-induced liver injury through prevention of Kupffer cell sensitization.
    Alcoholism, clinical and experimental research, 2005, Volume: 29, Issue:12 Suppl

    Topics: Animals; Chemical and Drug Induced Liver Injury; Endotoxins; Enzyme-Linked Immunosorbent Assay; Fema

2005
Peroxisome proliferated-activated receptor gamma ligand, Pioglitazone, does not prevent hepatic fibrosis in mice.
    International journal of molecular medicine, 2007, Volume: 19, Issue:1

    Topics: Animals; Carbon Tetrachloride; Cells, Cultured; Chemical and Drug Induced Liver Injury; Extracellula

2007
[A new case: pioglitazone hepatotoxicity].
    Medicina clinica, 2007, Jun-23, Volume: 129, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Female; Humans; Hypoglycemic Agents; Middle Aged; Pioglitazo

2007
Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
    BMJ (Clinical research ed.), 2000, Jul-29, Volume: 321, Issue:7256

    Topics: Chemical and Drug Induced Liver Injury; Chromans; Contraindications; Diabetes Mellitus, Type 2; Drug

2000
Hepatocellular injury in a patient receiving pioglitazone.
    Annals of internal medicine, 2001, Aug-21, Volume: 135, Issue:4

    Topics: Aged; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents

2001
Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy.
    Annals of internal medicine, 2002, Mar-19, Volume: 136, Issue:6

    Topics: Bilirubin; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Diabetes Mellitus, Typ

2002
"Did this drug cause my patient's hepatitis?" and related questions.
    Annals of internal medicine, 2002, Mar-19, Volume: 136, Issue:6

    Topics: Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inte

2002
Summary for patients. Liver damage in a person taking the diabetes drug pioglitazone.
    Annals of internal medicine, 2002, Mar-19, Volume: 136, Issue:6

    Topics: Bilirubin; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Diabetes Mellitus, Typ

2002